Core Viewpoint - Recently, Stone Pharmaceutical Group (01093) has seen a significant stock price increase due to a strategic partnership with AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects outside of mainland China and Hong Kong/Macau [1] Group 1: Financial Details - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for development and sales [1] - The subsidiary of Giant Bio (New Nuo Wei, 300765) is entitled to receive 35% of the upfront payment and subsequent milestone payments based on actual conditions [1] Group 2: Future Prospects - CICC anticipates that by 2025, the company will have achieved external licensing for oral small molecule GLP-1 ($120 million upfront), AstraZeneca strategic cooperation ($110 million upfront), irinotecan liposome ($15 million upfront), and ROR1ADC ($15 million upfront) [1] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC/SiRNA series, which are expected to continue generating external licensing opportunities and milestone revenue recognition [1]

Core Viewpoint - The recent partnership between Stone Pharmaceutical Group and AstraZeneca for the development and commercialization of eight innovative long-acting peptide drug projects is expected to significantly enhance the company's revenue potential through substantial upfront and milestone payments [1] Group 1: Financial Impact - Stone Pharmaceutical Group's stock rose over 5% in early trading, reflecting positive market sentiment regarding the AstraZeneca collaboration [1] - AstraZeneca will pay a total of $1.2 billion in upfront payments and up to $3.5 billion in cumulative milestone payments for the projects [1] - The company is projected to receive 35% of the initial payment from the collaboration, along with potential future milestone payments and royalties [1] Group 2: Development Pipeline - The company has successfully licensed out several projects, including oral small molecule GLP-1 and others, which are expected to generate significant revenue [1] - The research pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, indicating ongoing potential for further licensing agreements and milestone revenue recognition [1]

Core Viewpoint - CICC maintains "outperform" rating for CSPC Pharmaceutical Group (01093) and raises target price by 9.1% to HKD 12, while keeping profit forecasts for 2025 and 2026 at CNY 4.76 billion and CNY 5.35 billion, respectively, and introducing a forecast of CNY 5.70 billion for 2027 [1] Group 1 - CSPC Pharmaceutical has signed a research and licensing agreement with AstraZeneca for the exclusive global development, production, and commercialization of eight innovative long-acting peptide drug projects, excluding mainland China and Hong Kong/Macau [2] - AstraZeneca will pay a total of USD 1.2 billion in upfront payments and up to USD 3.5 billion in cumulative milestone payments for development and sales, with Giant Biologics (a subsidiary of New Horizon (300765)) entitled to 35% of the upfront payment and subsequent milestone payments [2] Group 2 - The company is betting on long-acting peptide drugs to compete in the weight loss and metabolic market, with its drug SYH2082 progressing to Phase I clinical trials as a monthly injection GLP1R/GIP agonist [3] - Pfizer's acquisition of Metsera for USD 10 billion highlights the competitive landscape, as Metsera's proprietary NuSH platform enables a long half-life for its weight loss drug MET-097 [3] Group 3 - CSPC has achieved significant external licensing agreements in 2025, including USD 120 million for oral small molecule GLP-1, USD 110 million for the AstraZeneca strategic partnership, and USD 15 million for ROR1ADC, indicating a trend towards regular income from external licensing [4] - The company's R&D pipeline includes advanced innovative assets such as EGFR ADC and SiRNA series, which are expected to lead to further successful licensing and milestone revenue recognition [4]